Skip to content

Article/Intelligence

KKR-Backed Headlands Research Taps Advisor for Potential Sale

Share on X (opens in a new window) Share on Facebook (opens in a new window) Share on LinkedIn (opens in a new window)

Reporting: Armie Margaret Lee

KKR-backed clinical trial site organization Headlands Research has hired Houlihan Lokey to explore a potential sale, according to industry sources.

Based in Lake Worth, Fla., Headlands has more than 20 trial sites across the United States and Canada. It focuses on areas including mental health, the central nervous system and vaccines.

KKR invested in Headlands in 2018 through its Health Care Strategic Growth Fund.

In 2019, Headlands acquired six clinical research centers spanning three organizations: Centex Studies, Clinical Research Atlanta and Okanagan Clinical Trials. Headlands’ other acquisitions include Peninsula Research Associates in 2022, Clinvest Research in 2023 and Trial Management Associates in 2024.

Recent deals in the clinical research site sector include Webster Equity Partners’ sale of CenExel Clinical Research Inc. to BayPine LP in April, reportedly for about $1.5 billion. Webster will retain a minority stake in CenExel. Blue Owl provided more than $600 million in debt financing to back the transaction, and the pricing was in the SOFR+450 bps-500 bps range, Octus, formerly Reorg, reported in April.

Last year, Genstar Capital LLC bought a majority stake in Flourish Research, marking an exit by NMS Capital LLC. The Flourish transaction was done at an EBITDA multiple in the high teens, Octus reported in September.

KKR had no comment, and Houlihan declined to comment. A Headlands representative did not immediately respond to a request for comment.

This publication has been prepared by Octus, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2025 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.